Letrozole Cristers (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal and peripheral androgens into estrogens. By inhibiting this conversion, circulating estrogen levels fall dramatically, depriving hormone‑sensitive breast cancer cells of the estrogenic stimulus required for their proliferation.

The specific dose and dosing schedule of Letrozole are determined by the prescribing clinician based on the individual patient's condition, treatment stage and overall health. Physicians follow approved guidelines and adjust the regimen as needed for safety and efficacy.

Letrozole is contraindicated in pregnancy and is not recommended for breastfeeding women. It can interfere with fetal development and may be excreted in breast milk, posing potential risks to the infant. Effective contraception is advised for women of child‑bearing potential while on therapy.

To place an order, submit an enquiry on the Letrozole Cristers product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole, an aromatase inhibitor, lowers estrogen production, whereas tamoxifen is a selective estrogen receptor modulator that blocks estrogen receptors in breast tissue while acting as an agonist elsewhere. Letrozole is generally preferred for postmenopausal patients due to higher efficacy in reducing recurrence, while tamoxifen remains a key option for premenopausal women.

Letrozole Cristers should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Letrozole is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing instructions provided by their healthcare professional.

Serious adverse events include severe liver injury, significant bone loss leading to fractures, and thromboembolic complications such as pulmonary embolism. Patients should report symptoms like persistent abdominal pain, sudden weakness, shortness of breath or unexplained bruising to their physician promptly.

Letrozole is contraindicated in premenopausal women, pregnant or breastfeeding individuals, and patients with known hypersensitivity to letrozole or any component of the formulation. Caution is also advised for those with severe hepatic impairment or uncontrolled cardiovascular disease.